Page 45 - 78_04

BASES
MOLECULARES
DE
LA
ESQUIZOFRENIA

20. Owen,
M.J.;
Craddock,
N.
&
O'Donovan,
M.
C.
(2005)
Schizophrenia:
genes
at
last?
Trends

in
Genetics
21,
518-­-525.

21. Niemi,
L.
T.;
Suvisaari,
J.
M.;
Tuulio-­-Henriksson,

A.
&
Lönnqvist,
J.
K.
(2003)
Childhood

developmental
abnormalities
in
schizophrenia:
evidence
from
high-­-risk
studies.

Schizophrenia
Research
60,
239-­-258.

22. Snyder,
S.
H.
(2006)
Dopamine
receptor
excess
and
mouse
madness.
Neuron
49,
484-­-485.

23. Carlsson,
A.
(1988)
The
current
status
of
the
dopamine
hypothesis
of
schizophrenia.

Neurospsychopharmacology.
1,
179-­-186.

24. Javitt,
D.
C.
(1987)
Negative
schizophrenic
syntomatology
and
the
PCP
(phencyclidine)

model
of
schizophrenia.
Hillside
Journal
of
Clinical
Psychiatry
9,
12-­-35.

25. Lang,
U.
E.;
Puls,
I.;
Müller,
D.
J.;
Strutz-­-Seebohm,
N.
&
Galliant,
J.
(2007)
Molecular

mechanisms
of
schizophrenia.
Cellular
Physiology
and
Biochemistry
20,
687-­-702).

26. Javitt,
D.
C.
&
Zukin,
S.
R.
(1991)
Recent
advances
in
the
phencyclidine
model
of

schizophrenia.
American
Journal
of
Psychiatry
148,
1301-­-1308.

27. Javitt,
D.C.
(2007)
Glutamate
and
schizophrenia:
phencyclidine,
N-­-methyl-­-D-­-aspartate

receptors,
and
dopamine-­-glutamate
interactions.
International
Review
of
Neurobiology

78,
69-­-108.

28. Lindsley
C.
W.;
Shipe
W.
D.;
Wolkenberg
S.
E.;
Theberge
C.
R.;
Williams,
D.
L.;
Sur,
C.
&

Kinney
G.
G.
(2006)
Progress
towards
validating
the
NMDA
receptor
hypofunction

hypothesis
of
schizophrenia.
Current
Topics
in
Medical
Chemistry
6,
771-­-785.

29. Watis,
L.;
Chen
S.
H.;
Chua,
H.
C.;
Chong,
S.
A.
&
Sim,
K.
(2008)
Glutamatergic
abnormalities

of
the
thalamus
in
schizophrenia:
a
systematic
review
Journal
of
Neural
Transmission

115,
493-­-511.

30. Millan,
M.
J.
(2005)
N-­-methyl-­-D-­-aspartate
receptors
as
a
target
for
improved
antipsychotic

agents:
novel
insights
and
clinical
perspectives.
Psychopharmacology
179,
30-­-53.

31. Olney,
J.
W.;
Newcomer,
J.
W.
&
Farber,
N.
B.
(1999):
NMDA
receptor
hypofunction
model

of
schizophrenia.
Journal
of
Psychiatry
Research
33,
523-­-533.

32. Moghaddam,
B.
(2003)
Bringing
order
to
the
glutamate
chaos
in
schizophrenia.
Neuron

40,
881-­-884.

33. Goldstein,
M.
&
Deutch,
A.
Y.
(1992)
Dopaminergic
mechanisms
in
the
pathogenesis
of

schizophrenia.
FASEB
Journal
6,
2413-­-2421.

34. Javitt,
D.
C.;
Sershen,
H.;
Hashim,
A.
&
Lajtha,
A.
(2000)
Inhibition
of
striatal
dopamine

release
by
glycine
and
glycyldodecylamide.
Brain
Research
Bulletin
52,
213-­-216.

35. Javitt,
D.
C.
(2004)
Glutamate
as
a
therapeutic
target
in
psychiatric
disorders
Molecular

Psychiatry
9,
984-­-997.

36. Lechner,
S.
M.
(2006)
Glutamate-­-based
therapeutic
approaches:
inhibitors
of
glycine

transport.
Current
Opinion
on
Pharmacology.
6,
75-­-81.

37. Thomsen,
C.
(2006)
Glycine
transporter
inhibitors
as
novel
antipsychotics.
Drug

Discovery:
Therapeutic
Strategies
3,
539-­-545.

38. Lindsley,
C.
W.;
Shipe,
W.
D.;
Wolkenberg,
S.
E.;
Theberge,
C.R.;
Williams,
D.
L.
Jr.;
Sur.
C.
&

Kinney,
G.
G.
(2006)
Progress
towards
validating
the
NMDA
receptor
hypofunction

hypothesis
of
schizophrenia.
Current
Topics
in
Medicinal
Chemistry
6,
771-­-785.

39. Descarries,
L.;
Bérubé-­-Carrière,
N.;
Riad,
M.;
Bo,
G.
D.;
Méndez,
J.
A.
&
Trudeau,
L.
E.
(2007)

Glutamate
in
dopamine
neurons:
synaptic
versus
diffuse
transmission.
Brain
Research

Reviews
58,
290-­-302.

40. Millan,
M.
J.
(2005)
N-­-Methyl-­-D-­-aspartate
receptors
as
a
target
for
improved
antipsychotic

agents:
novel
insights
and
clinical
perspectives.
Psychopharmacology
(Berlin)
179,
30-­-53.

443